Therapy News and Research

RSS

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year. The new guideline suggests use of preventive treatments and advises against routinely screening patients after surgery using ultrasound imaging.

1 Oct 2011

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

1 Oct 2011

Viewpoints: Sebelius on improving care; Samuelson on health costs; Durenberger on exporting U.S. system

Far too many Americans still go without the best care. That's why the Obama administration has joined with Truman Medical Centers and more than 2,500 other hospitals nationwide, along with thousands of employers, health insurers, provider organizations and patient advocates, to launch the Partnership for Patients … Over the next three years, we will reduce preventable injuries in hospitals by 40 percent. And we will cut hospital re-admissions by 20 percent, targeting the return trips that should never have occurred.

1 Oct 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, cannot enjoy a normal lifestyle. "The aortic valve is a gatekeeper," says Marco Costa, MD, of University Hospitals (UH) Case Medical in Cleveland.

From Medtronic 1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Nutrition experts participated in PN Safety Summit to discuss safety of PN therapy, patient care

Recent safety concerns in the preparation and delivery of parenteral nutrition, commonly referred to as intravenous nutrition, prompted leaders from several major organizations to participate in a PN Safety Summit on September 23, 2011.

From Baxter International Inc. 1 Oct 2011

The West Clinic forms new comprehensive breast center

The West Clinic, the Mid-South's premier cancer practice, is pleased to announce the formation of The West Clinic Comprehensive Breast Center, a multidisciplinary breast center, which will be the first center of its kind in the region.

1 Oct 2011

Scientists discover that DNA modifications in brain cells change due to stimulated brain activity

Johns Hopkins scientists investigating chemical modifications across the genomes of adult mice have discovered that DNA modifications in non-dividing brain cells, thought to be inherently stable, instead underwent large-scale dynamic changes as a result of stimulated brain activity.

1 Oct 2011

UCI study shows promise of metabolic therapy for autoimmune diseases

A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.

1 Oct 2011

USAID interviews Kenyan government staff regarding Cabinet memorandum outlining HIV program fundraising options

USAID's "IMPACTblog" interviews Regina Ombam, head of strategy for the Kenya National AIDS Control Council (NACC), and Irene Mukui, the antiretroviral therapy (ART) program manager for Kenya's National AIDS and STI Control Program, regarding a Cabinet memorandum prepared by the NACC in March that outlines ways to raise funds for HIV programming.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

First Edition: September 30, 2011

Today's headlines include reports about how new and old health policy positions are playing on the campaign trail.

30 Sep 2011

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how scientific findings from St. Jude can be translated into therapies and tests that in addition to helping children, also help adults.

30 Sep 2011

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who've provided an invaluable contribution to medical science and healthcare.

30 Sep 2011

Researchers develop HTGTS to map translocatome in the genome

Researchers at Children's Hospital Boston and the Immune Disease Institute (IDI) have created a method for mapping "hot spots" in the genome where chromosomes are most likely to break and recombine, knowledge that helps define the rules that govern when and where breaks occur.

30 Sep 2011

MU researchers examine use of propranolol to improve primary traits linked with autism

Most drug therapy interventions for people with autism have targeted psychiatric problems, including aggression, anxiety and obsessive behavior. Now, University of Missouri researchers are examining the use of propranolol to improve the primary traits associated with autism - difficulty with normal social skills, language and repetitive behaviors.

30 Sep 2011

First patient in Turkey with Total Artificial Heart attends TUYOD meeting

In May 2011, Omer Bayrak made headlines when he became the first patient in Turkey to be discharged from the hospital using the Freedom® portable driver to power his SynCardia temporary Total Artificial Heart. Since returning home to wait for a matching donor heart, Mr. Bayrak has been enjoying his new-found celebrity as "the only man in Turkey who lives without a heart."

30 Sep 2011

Therapy News and Research

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

Viewpoints: Sebelius on improving care; Samuelson on health costs; Durenberger on exporting U.S. system

Blueberry powder may control triple negative breast cancer

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Nutrition experts participated in PN Safety Summit to discuss safety of PN therapy, patient care

The West Clinic forms new comprehensive breast center

Scientists discover that DNA modifications in brain cells change due to stimulated brain activity

UCI study shows promise of metabolic therapy for autoimmune diseases

USAID interviews Kenyan government staff regarding Cabinet memorandum outlining HIV program fundraising options

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Baxter seeks European marketing authorization for HyQ to treat PI

First Edition: September 30, 2011

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

Researchers develop HTGTS to map translocatome in the genome

MU researchers examine use of propranolol to improve primary traits linked with autism

First patient in Turkey with Total Artificial Heart attends TUYOD meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News